Opportunity Information: Apply for CDC RFA PS 24 00470101SUPP24
This CDC funding opportunity is a competitive supplemental award tied to the broader PS24-0047 cooperative agreement that supports High-Impact HIV Prevention and Surveillance Programs for Health Departments. CDC is making about 7 million dollars available specifically to accelerate progress in Ending the HIV Epidemic (EHE) jurisdictions by increasing uptake of pre-exposure prophylaxis (PrEP). The central policy target driving this supplement is the national HIV prevention goal of reaching 50 percent PrEP coverage by the end of 2025, and the supplement is designed to help funded jurisdictions close gaps quickly in places where PrEP need is high but use remains comparatively low.
Eligibility is limited by statute to the 32 state, local, and territorial health department jurisdictions that are already receiving EHE resources under PS24-0047, meaning this is not an open competition for new applicants outside that existing cohort. The applicants are governmental health departments (state, county, city/township, and special district governments) and the award mechanism is a cooperative agreement, which typically means CDC anticipates substantial involvement through technical assistance, coordination, performance expectations, and ongoing collaboration rather than a hands-off grant.
Programmatically, the supplemental funding prioritizes jurisdictions where PrEP uptake is lagging among populations that are disproportionately affected by HIV and also face low PrEP prescription rates. The notice calls out priority populations including Black and Latino gay, bisexual, and other men who have sex with men (MSM), as well as Black cisgender women and Black transgender women. The intent is to provide additional resources and flexibility so recipients can move faster on strategies that directly remove real-world barriers to PrEP use, especially barriers linked to structural and social inequities (for example, challenges with healthcare navigation, access points, stigma, cost-related gaps, and logistical hurdles that keep people from starting or staying on PrEP).
A major emphasis of the supplement is expanding and enhancing PrEP service delivery supports that are not fully covered by other funding sources. In practical terms, that includes strengthening patient navigation and case management approaches that help people identify PrEP options, connect to prescribing providers, complete needed lab work, resolve insurance or payment issues, and remain engaged in care over time. The supplement also supports efforts to improve access to and utilization of existing PrEP services, suggesting jurisdictions should focus on making current capacity easier to find and use for the people who need it most, rather than building parallel systems that do not connect to established services.
In addition to PrEP expansion, the supplement expects jurisdictions to incorporate related prevention elements by increasing awareness and access to HIV non-occupational post-exposure prophylaxis (PEP) and doxycycline post-exposure prophylaxis (doxy PEP). This component is framed as an integrated prevention approach that reaches clinicians, non-clinical community-based organizations (CBOs), and individuals at risk for acquiring HIV. The idea is to strengthen the broader prevention ecosystem so people who have a recent exposure can access PEP promptly, and communities and providers have better information and pathways related to doxy PEP where appropriate, while still keeping the primary focus on scaling PrEP.
Timing is short and intentionally urgent. The period of performance for the supplemental funding runs from September 30, 2024 through May 31, 2025, an 8-month window aimed at near-term acceleration toward the 2025 coverage goal. Recipients may request to continue these supplemental activities into PS24-0047 Budget Year 2 (June 1, 2025 through May 31, 2026), but the initial supplement is structured to drive rapid implementation. Importantly, recipients are expected to implement this supplemental work concurrently with all required activities under the main PS24-0047 award, meaning jurisdictions need plans that integrate the supplemental PrEP acceleration efforts into their existing EHE and HIV prevention and surveillance infrastructure rather than treating it as a separate, standalone initiative.
From an administrative standpoint, the opportunity is listed under CFDA 93.940 and is managed by CDCs National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). The opportunity number is CDC RFA PS 24 00470101SUPP24, the application deadline shown is August 31, 2024, and CDC anticipates a small number of awards (expected awards listed as 4). The listing shows an award ceiling of 0, which typically indicates that a specific maximum was not published in the summary field rather than that funding is unavailable; the narrative clearly states CDC expects to distribute approximately 7 million dollars total through this supplemental competition among eligible jurisdictions.
Overall, this supplemental NOFO is best understood as a targeted, short-duration investment to help EHE-funded health departments rapidly increase equitable PrEP coverage in the highest-need communities, using hands-on navigation and access strategies, while also strengthening complementary prevention pathways for PEP and doxy PEP through coordinated work with clinical partners and community organizations.Apply for CDC RFA PS 24 00470101SUPP24
- The Centers for Disease Control - NCHHSTP in the health sector is offering a public funding opportunity titled "High-Impact HIV Prevention and Surveillance Programs for Health Departments: Accelerating Pre-Exposure Prophylaxis (PrEP) Uptake for Ending the HIV Epidemic in the United States" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.940.
- This funding opportunity was created on 2024-08-01.
- Applicants must submit their applications by 2024-08-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health
Next opportunity: Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
Previous opportunity: Pregnancy and Postpartum Hypertension Control Initiative
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS 24 00470101SUPP24
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS 24 00470101SUPP24) also looked into and applied for these:
| Funding Opportunity |
|---|
| Ensuring Social Protection by Empowering and building Resiliency for Adolescents, Nuclear families, Children, and caregivers affected by HIV/AIDS (ESPERANÇA) Apply for 72065624RFA00005 Funding Number: 72065624RFA00005 Agency: Mozambique USAID-Maputo Category: Health Funding Amount: $40,000,000 |
| Short Courses on Utilizing the NIH Stage Model to Develop Behavioral Interventions to Promote Healthy Aging (R25 - Independent Clinical Trial Not Allowed) Apply for RFA AG 25 029 Funding Number: RFA AG 25 029 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (S15 Clinical Trial Not Allowed) Apply for PAR 24 259 Funding Number: PAR 24 259 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed) Apply for RFA AI 24 071 Funding Number: RFA AI 24 071 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID’s Health Financing, Governance, and Information Systems Strengthening Activity Apply for 72066024RFI00005 Funding Number: 72066024RFI00005 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: Case Dependent |
| Request for Information-USAID/RDMA Thailand HIV Key Population Civil Society Organization Leadership Apply for 72048624RFI00002 Funding Number: 72048624RFI00002 Agency: Thailand USAID-Bangkok Category: Health Funding Amount: $35,000,000 |
| Suivi communautaire des Programmes et Politiques liés au VIH Apply for 72068824RFI00001 Funding Number: 72068824RFI00001 Agency: Mali USAID -Bamako Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required) Apply for RFA AT 24 011 Funding Number: RFA AT 24 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Grants to Rigorously Evaluate Innovative and Promising Strategies to Prevent Firearm-Related Violence and Injuries Apply for RFA CE 25 030 Funding Number: RFA CE 25 030 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $650,000 |
| Rigorous Evaluation of Community- and Societal-Level Primary Prevention Approaches to Prevent Adverse Childhood Experiences (ACEs): Expanding the Best Available Evidence Apply for RFA CE 25 025 Funding Number: RFA CE 25 025 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $450,000 |
| Grants to Support New Investigators in Conducting Research Related to Preventing Interpersonal Violence Impacting Children and Youth Apply for RFA CE 25 029 Funding Number: RFA CE 25 029 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $150,000 |
| Effectiveness Research to Prevent Polysubstance-Impaired Driving Apply for RFA CE 25 028 Funding Number: RFA CE 25 028 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $350,000 |
| Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose Apply for RFA CE 25 149 Funding Number: RFA CE 25 149 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Environmental Health Specialists Network (EHS-Net) Practice-based Research to Improve Food Safety Apply for RFA EH 25 011 Funding Number: RFA EH 25 011 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $200,000 |
| Rigorously Evaluating Programs and Policies to Prevent Child Sexual Abuse and Problematic Sexual Behavior among Youth Apply for RFA CE 25 026 Funding Number: RFA CE 25 026 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $400,000 |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 25 021 Funding Number: RFA CE 25 021 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $400,000 |
| Evaluate STEADI-based Fall Prevention in Assisted Living Facilities Apply for RFA CE 25 027 Funding Number: RFA CE 25 027 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Formative Research of Community-led Primary Prevention Approaches to Address Elevated Risk of Intimate Partner Violence & Sexual Violence Apply for RFA CE 25 032 Funding Number: RFA CE 25 032 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $375,000 |
| Rigorously Evaluating Primary Prevention Strategies for Intimate Partner Violence and Sexual Violence Apply for RFA CE 25 031 Funding Number: RFA CE 25 031 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF) Apply for HRSA 25 046 Funding Number: HRSA 25 046 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS 24 00470101SUPP24", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.